Rongsheng Biology
逻晟生物
Rongsheng Biology (宁康瑞珠生物制药) is a clinical-stage innovative biotech company founded in 2019 in Zhuhai, with a team drawn from frontline R&D and operations at Merck, Novartis, Roche, and BMS . Its core platform is the proprietary Membrane-Anchored Drug Design (MADD) technology, which it uses to develop first-in-class or best-in-class therapeutics for metabolic and immunological diseases . The MADD platform has already achieved proof-of-concept in humans, and the company is building out a pipeline of differentiated candidates across multiple indications . As of April 2026, it had completed a Series A round of over 100 million RMB .
AI-generated — may contain errors, please verify.
Coverage
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Li Feng: One Chart to Decode Biotech Innovation Opportunities | Your Complete Guide to the FreeS Fund 2020 Biomedical Summit
Three Livestreams and One Offline Symposium, Decoding the Era of Biomedical Innovation
FreeS Fund Healthcare Open Day Is Here: Entering the Grand Era of Biomedical Innovation
Looking for China's Genentech, Moderna, Alnylam, Spark, Nimbus Therapeutics
